Background: Multiple case reports suggest that olmesartan may be linked to sprue-
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| Data sources
We identified eligible patients from 5 US databases covering the The commercial plan provides primarily employer-based insurance benefits for working individuals; Medicaid provides insurance benefits for those with low income; and Medicare provides insurance benefits for those aged 65 years or older as well as those with certain disabilities. Combined, these databases cover around 100 million individuals and represent each of the 3 main insured segments of the population in the US. These databases include information on demographic and enrolment records, in-patient and out-patient diagnoses and procedures, and out-patient pharmacy dispensings (Data S1). This study was approved by the Institutional Review Board of the Brigham and Women's Hospital.
| Study population and study drugs
From each database, we identified patients who initiated ARB treatment with either olmesartan or other ARBs (candesartan, eprosartan, irbesartan, losartan, telmisartan, valsartan, azilsartan, including single and combination products). ARB initiation was defined as a first ARB prescription dispensing during the study period with no dispensings for any ARBs in the preceding 180 days during which patients were required to have continuous health plan enrolment. The index date was defined as the date of the first ARB prescription. We excluded those with age less than 20 years in Optum and MAX or less than 65 years in the Medicare databases (PACE, PAAD and CareMark) on the index date, those with missing age or ambiguous sex information, and those who initiated both olmesartan and other ARBs on the same date.
| Outcomes and follow-up
Given that no specific diagnosis code is available for ARB-associated sprue-like enteropathy, which had not been described prior to the first published case series, 6 and given the similarity in presentation, we used coeliac disease as a primary surrogate outcome, as was done in the analyses performed by the FDA. 19, 20 To identify potential diagnoses or symptoms related to enteropathy that were not coded as coeliac disease, our study team, with expertise in gastroenterology, pharmacy and epidemiology, reviewed available case series or reports and observational studies 6, [11] [12] [13] [14] [15] [16] [17] [26] [27] [28] 19, 20 and 2 epidemiological studies, 26, 28 are provided in Table S1 .
Patients were followed from the index date to the earliest of the following: outcome occurrence, ARB treatment discontinuation or change, death, disenrollment from the health insurance programme, or the end of data in the respective database. ARB treatment discontinuation was defined using a grace period of 30 days between the end of one prescription and the date of the next prescription, if any.
ARB treatment change (switch or addition) was defined as a dispensing of another ARB for olmesartan initiators and a dispensing of olmesartan for other ARB initiators.
| Covariate assessment
We measured a large number of potential baseline confounders including age on the index date, sex and calendar year of the index date, as well as prior resource utilisation, comorbidities and other medication use within 180 days preceding the index date. We also calculated a combined comorbidity score, which comprises 20 clinical conditions derived from the Charlson Index and the Elixhauser Index. 29 Measures of resource utilisation included numbers of hospital admissions, out-patient visits and nursing home admission.
Comorbidities were ascertained based on in-patient and out-patient diagnosis files and medication use was derived from out-patient pharmacy dispensing claims. Table S2 provides detailed covariate information.
| Statistical analyses
Using the covariates mentioned above, we estimated baseline propensity scores (PS) using logistic regression models to predict the probability of initiating olmesartan vs other ARBs. Because we had many more patients who initiated other ARBs, we matched up to 10 patients who initiated other ARBs to each patient who initiated olmesartan using a nearest-neighbour algorithm without replacement and with a maximum matching calliper of 0.025 on the PS scale. 30 We used Cox proportional hazard models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) in the 1:10 variable-ratio matched cohort. To account for the variable-ratio matching, the Cox model was stratified on matching ratio. 30 Variable-ratio matching produces covariate balance within matched set but not marginally in the overall matched population. 30 We therefore randomly selected 1 initiator of other ARBs from each set of patients matched to each olmesartan initiator and examined whether adequate balance in covariates was achieved between treatment groups using standard differences 31 among this sample.
We identified study cohorts, extracted information on variables, fit PS models, and performed PS matching separately within each database. We fit separate Cox proportional hazards regression models in each database to obtain database-specific estimates. We computed standardised differences across the databases for each variable using pooled means and standard deviations (SD). We pooled the 1:10 variable-ratio matched cohorts from the 5 databases and used Cox models, stratified on matching ratios, to estimate sum- Finally, some patients who experience severe diarrhoea and weight loss may have accompanying dehydration leading to acute kidney injury (AKI). 6, 11, 12, 14 To assess whether olmesartan is associated with a higher rate of enteropathy-related AKI, we examined those cases involving a hospitalised AKI diagnosis (ICD-9-CM code: 584) within 3 months before or after the first diagnosis of coeliac disease.
To focus on incident cases of enteropathy, we conducted an analysis by excluding patients with any diagnosis of coeliac disease, malabsorption, concomitant diagnoses of diarrhoea and weight loss, or non-infectious enteropathy within 180 days before the index date. Given that diabetes may be associated with bacterial overgrowth, diabetic diarrhoea or coeliac disease, 33 we also conducted another analysis by excluding those with any diabetes diagnosis at baseline.
| Subgroup analyses
Because older patients are often more vulnerable to adverse drug reactions and coeliac disease is more common in women, 7 we conducted subgroup analyses to examine potential effect measure modification by age ( ≥ 65 and < 65 years) and sex. Based on case reports, enteropathy-related symptoms often occur months or even years after olmesartan initiation. 6, 11, 12, 14, 16, 17 To assess for a dura- 
| Baseline characteristics
A total of 1 928 469 eligible patients were identified across the 5 databases; 350 790 initiated olmesartan (18%) and 1 577 679 initiated other ARBs (82%) ( Figure S1 and Table S4 ). Most patients were enrolled in Optum (47%), followed by MAX (42%). Among patients who initiated other ARBs, valsartan (n = 679 039) was the most common, followed by losartan (n = 543 797), irbesartan (n = 171 239) and telmisartan (n = 123 089). The mean (SD) age of the cohort was 55 (14) years and 58% were female. Most patients had hypertension (77%); 39% had dyslipidemia and 28% had diabetes.
Before matching, patients who initiated olmesartan were younger and had lower medical resource utilisation as compared to patients who initiated other ARBs. Patients who initiated olmesartan were also less likely to have had a diagnosis of ischaemic heart disease, heart failure, diabetes and chronic kidney disease, and have used b blockers, nitrates, antiplatelet drugs and antidiabetic drugs (Table 1 and 96% of the total study cohort) were included in the analysis (Figure S1 and Table S4 ). PS matching resulted in good balance in baseline characteristics between treatment groups (Table 1 and   Table S5a -f).
| Follow-up and outcomes
The follow-up duration did not vary materially across databases Table 2 (across databases) and Table S6a -b (in individual databases).
In the primary analyses, the crude HRs comparing olmesartan to (Table 3) . Use of olmesartan was consistently associated with higher rates of each outcome in individual databases, although estimates tended to be less precise (Table S7 ).
| Sensitivity analyses
In the "first exposure carried forward" approach, the mean follow-up duration was 857 days and the adjusted HR for coeliac disease was (Table S8) .
Of eligible cohort members, 2% (n = 36 196) had diagnoses of coeliac disease, malabsorption, concomitant diagnoses of diarrhoea and weight loss, or non-infectious enteropathy and 28%
(n = 544 676) had a diabetes diagnosis before the index date.
Excluding these patients led to adjusted HRs for coeliac disease that was materially similar to those from the primary analyses (Table S8 ).
| Subgroup analyses
The adjusted HRs were higher in older patients but did not differ between female and male patients ( the alimentary tract and might be involved in angiotensin IImediated transforming growth factor b (TGF-b) signalling, [37] [38] [39] [40] [41] [42] which is necessary for the maintenance of gut immune homeostasis. 43, 44 AT2 receptors are expressed in the duodenum and jejunum and may induce intestinal epithelial cell apoptosis. [37] [38] [39] The translocation of AT2 receptors from cytosol to external membranes has been observed in the presence of high concentrations of angiotensin II in rat smooth muscle cells. 45 As compared to other ARBs, olmesartan has a greater affinity for inhibiting AT1. 4, 46 Thus, it is possible that olmesartan may cause greater disruption of gut immune homeostasis. In addition, if AT1 receptors become saturated by olmesartan, circulating angiotensin II may be more likely to bind to AT2 receptors and lead to pro-apoptotic effects and intestinal adverse reactions. More research exploring these complex biological pathways would be helpful to further distinguish olmesartan-induced enteropathy and coeliac disease.
Our study and the FDA's Sentinel system 19, 20 used coeliac disease as a primary surrogate outcome for ARB-associated enteropathy outcomes. In our ARB cohort with a mean age of 55 years, the incidence rates per 1000 person-years were 0.98 for females and 0.61 for males. Similarly, the FDA found incidence rates per 1000
T A B L E 2 Follow-up and outcome event rates after propensity score matching, by ARB group Olmesartan (n = 350 430) Other ARBs (n = 1 504 562) Data were weighted by matching ratio and were pooled across databases using random-effects meta-analysis.
T A B L E 3 Hazard ratios and 95% confidence intervals comparing use of olmesartan vs other ARBs after propensity score matching
Outcome
In-patient or outpatient diagnoses
In-patient diagnoses only ARBs. 20 Another US population-based study including patients with a median age of 38 years found incidence rates of 0.21 and 0.14 per 1000 person-years for female and male patients respectively. 47 While coeliac disease is more common among females than males, sex does not appear to modify the association between olmesartan and sprue-like enteropathy. We did not observe differences in HRs for olmesartan vs other ARBs by sex (Table 4) . Another French nationwide cohort study also did not observe HRs of olmesartan vs ACE inhibitors differ apparently for individual enteropathy outcomes by sex. 28 Further research focusing on a sex-specific effect may be helpful to elucidate whether sex is an important effect modifier of this association.
The results of this study should be interpreted in the context of prior epidemiological research. No association between olmesartan and intestinal adverse reactions was observed in the Randomized
Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial 24, 25 and in a US cohort study 26 that enrolled diabetic patients only. One possible explanation for the discrepancy in results between these studies and our study is that these studies assessed nonspecific gastrointestinal events, which are much more common than the outcomes that we studied, and which may have obscured an association with a more specific enteropathy outcome. Also, as enteropathy is a rare event, clinical trials or single-database studies may be underpowered to detect differences between treatment groups.
In the present study, we used data from 5 large databases that cover geographically, socioeconomically and clinically diverse populations. We identified all incident ARB users without restricting to diabetic patients as the eligible cohort, defined enteropathy-related outcomes in multiple ways, 6, [11] [12] [13] [14] [15] [16] [17] 19, 20, [24] [25] [26] [27] [28] and followed patients longitudinally. These approaches are relative strengths of our study because they facilitate the study of uncommon outcomes and promote the generalisability of the findings. As compared to the French cohort study that suggested that olmesartan was associated with higher rates of hospitalised coeliac disease and malabsorption as compared to ACE inhibitors, 28 our study provides further information on the comparative safety of olmesartan and other ARBs, as a whole group or individual medications (valsartan, losartan, irbesartan and telmisartan). Our duration-response and dose-response findings also bolster our findings.
There are important limitations of administrative healthcare data and of our study that must be considered when interpreting our results. First, pharmacy claims data provide accurate information about the prescriptions that patients fill, but they do not necessarily reflect whether patients consume the medications, which can lead to exposure misclassification. However, this misclassification is expected to be nondifferential between our exposure groups and would likely lead to a bias towards the null. Second, in our primary analysis, we stopped following patients once they discontinued or changed their index ARB treatment. This reduced the possibility of exposure misclassification but resulted in a short mean follow-up duration (only 282 days). Also, unlike the previous French cohort in which 60% of patients were treated for more than 1 year and 34% treated for more than 2 years, 28 only 23% of patients in our study were treated for more than 1 year and 9% treated for more than 2 years. This precluded precise rate estimation for patients receiving ARB treatment for more than 2 years. However, our study reflects the actual use patterns of ARBs in real-world clinical settings in the US. Third, although we used multiple approaches for defining outcomes based on multiple diagnoses and symptoms identified in the literature; restricted outcomes to in-patient cases; required additional enteropathy-related diagnoses, endoscopic examination or hospitalised AKI episodes;
and excluded patients with potential underlying intestinal disorders or diabetes in sensitivity analyses, we acknowledge the possibility of outcome misclassification given that no validated diagnostic codes for ARB-induced enteropathy, no diet information, and no histological and coeliac serology testing results were available.
However, more than 90% of data included in our study covered the period before the first case series was published (June 2012).
Therefore, physicians were unlikely to be biased by specific ARB treatment when they diagnosed enteropathy-related outcomes or symptoms. Thus, we expect any outcome misclassification to be nondifferential between exposure groups. Finally, we used an active comparison design, controlled for a number of confounders, including immunosuppressants, which have been found to be associated with the occurrence of enteropathy, [48] [49] [50] and conducted PS matching to mitigate potential confounding. Nevertheless, we cannot rule out the possibility of unmeasured confounding, which is an inherent limitation of all observational studies.
In conclusion, we found evidence of a higher rate of enteropathy outcomes among initiators of olmesartan vs initiators of other ARBs although the absolute rate was low. Considering the widespread, long-term use of olmesartan in clinical settings and more pronounced relative risk for older patients, those treated for longer periods and those treated with higher cumulative doses, the potential olmesartan-associated enteropathy deserves attention in clinical practice.
Until more evidence is available, clinicians should consider olmesartan as a potential cause when evaluating patients with enteropathy and should consider alternative ARBs for these patients. Prospective studies with primary data on sprue-like enteropathy outcomes, including histology and serology results, are warranted to comprehensively assess this safety issue.
